Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H.

J Bone Miner Res. 2014 Aug;29(8):1777-85. doi: 10.1002/jbmr.2216.

2.

Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H.

J Bone Miner Res. 2013 Jan;28(1):196-205. doi: 10.1002/jbmr.1716.

3.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51.

4.

Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.

Cosman F, Nieves JW, Zion M, Garrett P, Neubort S, Dempster D, Lindsay R.

J Clin Endocrinol Metab. 2015 Jul;100(7):2769-76. doi: 10.1210/jc.2015-1715.

PMID:
25961136
5.

Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH.

Osteoporos Int. 2008 Jul;19(7):1055-65. doi: 10.1007/s00198-007-0557-z.

PMID:
18283386
6.

The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.

Michalská D, Stepan JJ, Basson BR, Pavo I.

J Clin Endocrinol Metab. 2006 Mar;91(3):870-7.

PMID:
16352692
7.

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.

Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA.

J Bone Miner Res. 2007 Jan;22(1):149-57.

8.

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.

J Clin Endocrinol Metab. 2009 Oct;94(10):3772-80. doi: 10.1210/jc.2008-2719.

PMID:
19584192
9.
10.

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.

Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH.

J Bone Miner Res. 2013 Jun;28(6):1328-36. doi: 10.1002/jbmr.1853.

11.

Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.

Hofstetter B, Gamsjaeger S, Varga F, Dobnig H, Stepan JJ, Petto H, Pavo I, Klaushofer K, Paschalis EP.

Osteoporos Int. 2014 Dec;25(12):2709-19. doi: 10.1007/s00198-014-2814-2.

PMID:
25037600
12.

Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.

Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.

Nephrol Dial Transplant. 2009 May;24(5):1472-7. doi: 10.1093/ndt/gfn690.

13.

Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.

Cosman F.

Curr Osteoporos Rep. 2014 Dec;12(4):385-95. doi: 10.1007/s11914-014-0237-9. Review.

PMID:
25341476
14.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

PMID:
11889149
15.

Femoral strength in osteoporotic women treated with teriparatide or alendronate.

Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.

Bone. 2012 Jan;50(1):165-70. doi: 10.1016/j.bone.2011.10.002.

PMID:
22015818
16.

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.

J Bone Miner Res. 2005 Nov;20(11):1905-11.

17.

Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.

Panico A, Lupoli GA, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A, Granieri L, Iacono D, Lupoli G.

Med Sci Monit. 2011 Aug;17(8):CR442-448.

18.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75.

PMID:
16884968
19.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
20.

Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.

Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.

Osteoporos Int. 2015 Sep;26(9):2365-74. doi: 10.1007/s00198-015-3141-y. Erratum in: Osteoporos Int. 2015 Nov;26(11):2719-20.

Items per page

Supplemental Content

Support Center